Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,027Revenue $M262Net Margin (%)-10.1Z-Score17.6
Enterprise Value $M922EPS $-0.4Operating Margin %-9.5F-Score4
P/E(ttm))0Cash Flow Per Share $0.5Pre-tax Margin (%)-9.9Higher ROA y-yN
Price/Book7.210-y EBITDA Growth Rate %0Quick Ratio4.3Cash flow > EarningsY
Price/Sales3.75-y EBITDA Growth Rate %0Current Ratio4.3Lower Leverage y-yY
Price/Cash Flow54.0y-y EBITDA Growth Rate %-506.7ROA % (ttm)-15.7Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-19.3Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M31.5ROI % (ttm)1.3Gross Margin Increase y-yN

Gurus Latest Trades with GHDX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GHDXDavid Swensen 2013-03-31 Sold Out -2.8%$26.72 - $29.65
($28.5)
$ 32.3714%Sold Out0
GHDXDavid Swensen 2012-12-31 Buy 2.8%$26.42 - $36.8
($30.13)
$ 32.377%New holding, 37861 sh.37,861
GHDXDavid Swensen 2011-03-31 Sold Out -0.93%$21.08 - $26.18
($23.29)
$ 32.3739%Sold Out0
GHDXDavid Swensen 2010-12-31 Buy 0.93%$13.18 - $23.52
($17.74)
$ 32.3782%New holding, 38243 sh.38,243
GHDXGeorge Soros 2006-12-31 Sold Out -0.23%$13.85 - $23.89
($17.5)
$ 32.3785%Sold Out0
GHDXGeorge Soros 2006-09-30 Buy 0.23%$11.16 - $14.38
($13)
$ 32.37149%New holding, 236371 sh.236,371
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GHDX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


GHDX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Popovits Kimberly JPresident and CEO 2014-11-12Sell4,300$34.82-5.17 view
Cole G BradleyCOO 2014-11-10Sell4,000$35.35-6.59 view
LIVINGSTON RANDALL SDirector 2014-11-03Sell3,000$36.24-8.89 view
Popovits Kimberly JPresident and CEO 2014-10-13Sell3,000$30.787.28 view
Cole G BradleyCOO 2014-10-08Sell4,000$28.7714.77 view
Popovits Kimberly JPresident and CEO 2014-09-11Sell3,000$29.8210.73 view
Cole G BradleyCOO 2014-09-08Sell4,700$30.099.74 view
Shak StevenEVP of R&D 2014-08-14Sell13,348$27.3620.69 view
Popovits Kimberly JPresident and CEO 2014-08-12Sell3,000$26.0726.66 view
Popovits Kimberly JPresident and CEO 2014-07-14Sell3,000$26.5924.18 view

Press Releases about GHDX :

    Quarterly/Annual Reports about GHDX:

    News about GHDX:

    Articles On GuruFocus.com
    CEO of InVitae Corporation of Genomic Health Inc. Randal W. Scott Sold 30,000 Shares Jul 13 2012 
    Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Mar 16 2011 
    Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Mar 16 2011 
    Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Mar 14 2011 
    Genomic Health Inc. (GHDX) COO G Bradley Cole sells 2,500 Shares Mar 10 2011 
    Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
    Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
    Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Feb 16 2011 
    Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Feb 14 2011 
    Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Jan 19 2011 

    More From Other Websites
    Nasdaq stocks posting largest percentage decreases Nov 25 2014
    Results from Second Oncotype DX® Prostate Cancer Test Clinical Validation and First Decision Impact... Nov 19 2014
    Results from Second Oncotype DX® Prostate Cancer Test Clinical Validation and First Decision Impact... Nov 19 2014
    GENOMIC HEALTH INC Financials Nov 14 2014
    GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers Nov 10 2014
    10-Q for Genomic Health, Inc. Nov 08 2014
    GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report Nov 06 2014
    Genomic Health Q3 Loss Narrower than Expected, Revenues Lag Nov 06 2014
    Genomic Health beats 3Q profit forecasts Nov 04 2014
    Genomic Health beats 3Q profit forecasts Nov 04 2014
    Genomic Health Announces Third Quarter 2014 Financial Results and Reports Continued Growth in U.S.... Nov 04 2014
    GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 04 2014
    Genomic Health Announces Third Quarter 2014 Financial Results and Reports Continued Growth in U.S.... Nov 04 2014
    Genomic Health to Present at the Credit Suisse Annual Healthcare Conference Nov 04 2014
    Genomic Health to Present at the Credit Suisse Annual Healthcare Conference Nov 04 2014
    Q3 2014 Genomic Health Inc Earnings Release - After Market Close Nov 04 2014
    Genomic Health to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday,... Oct 28 2014
    Genomic Health to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday,... Oct 28 2014
    Should Genomic Health (GHDX) Be in Your Portfolio Now? Oct 15 2014
    Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as... Sep 29 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK